Optimal approach to stem cell mobilization in transplant-eligible multiple myeloma patients

Abstract

Multiple myeloma is a neoplastic disorder of plasma cells typically afflicting older individuals. Despite significant improvements in induction therapy and outcomes for transplant-ineligible newly diagnosed multiple myeloma (NDMM) patients, autologous stem cell transplant (ASCT) remains the standard of care for consolidation in transplant-eligible NDMM. Consequently, the optimal approach to stem cell mobilization remains critical. In this manuscript, we outline key updates to stem cell mobilization in NDMM patients. We describe the optimal number of cycles of induction prior to mobilization, emphasizing the need to balance the benefit of achieving improved depth of response by giving additional cycles of pre-transplant induction with the impact on stem cell yields. Additionally, we review ideal timing between the end of induction and initiation of mobilization to facilitate both a minimization of time off therapy as well as better communication and work flow between community providers and transplant centers. We also review different stem cell mobilization regimens with and without upfront CXCR4 inhibitors to optimize stem cell yields while considering both clinical outcomes and cost of care. Finally, we review optimal yields of CD34⁺ hematopoietic stem cells to minimize toxicity for ASCT and also consider optional utilization of stem cells for both salvage second ASCT and stem cell boosts for poor marrow function.

Keywords

Multiple myeloma / stem cell mobilization / autologous stem cell transplant / optimal approach

References

[1] Key statistics about multiple myeloma. Available from: https://www.cancer.org/cancer/types/multiple-myeloma/about/key-statistics.html [Last accessed on 21 May 2024]

[2] Cancer stat facts: myeloma. Available from: https://seer.cancer.gov/statfacts/html/mulmy.html [Last accessed on 21 May 2024]

[3] Costa LJ,Omel J,Kumar SK.Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States.Blood Adv2017;1:282-7 PMCID:PMC5727774

[4] Nishimura KK,van Rhee F.Long-term outcomes after autologous stem cell transplantation for multiple myeloma.Blood Adv2020;4:422-31 PMCID:PMC6988393

[5] Martino M,Gentile M,Cerchione C.Allogenic stem cell transplantation in multiple myeloma: dead or alive and kicking?.Panminerva Med2020;62:234-43

[6] Greil C,Finke J.Allogeneic stem cell transplantation in multiple myeloma.Cancers2021;14:55 PMCID:PMC8750583

[7] Facon T,Plesner T.Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial.Lancet Oncol2021;22:1582-96

[8] Durie BGM,Sexton R.Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT).Blood Cancer J2020;10:53 PMCID:PMC7214419

[9] Kumar SK,Cohen AD.Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial.Lancet Oncol2020;21:1317-30 PMCID:PMC7591827

[10] Richardson PG,Weller EA.Triplet therapy, transplantation, and maintenance until progression in myeloma.N Engl J Med2022;387:132-47

[11] Attal M,Hulin C.Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma.N Engl J Med2017;376:1311-20 PMCID:PMC6201242

[12] Gay F,Rota-Scalabrini D.Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial.Lancet Oncol2021;22:1705-20

[13] Sonneveld P,Boccadoro M.Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma.N Engl J Med2024;390:301-13

[14] Gay F,Dimopoulos MA.Results of the phase III randomized iskia trial: isatuximab-carfilzomib-lenalidomide-dexamethasone vs carfilzomib-lenalidomide-dexamethasone as pre-transplant induction and post-transplant consolidation in newly diagnosed multiple myeloma patients.Blood2023;142:4

[15] Solimando AG,Leone P.Drug resistance in multiple myeloma: Soldiers and weapons in the bone marrow niche.Front Oncol2022;12:973836 PMCID:PMC9533079

[16] Gertz MA,Lacy MQ.Stem cell transplantation in multiple myeloma: impact of response failure with thalidomide or lenalidomide induction.Blood2010;115:2348-53

[17] Kapoor P,Dispenzieri A.Importance of achieving stringent complete response after autologous stem-cell transplantation in multiple myeloma.J Clin Oncol2013;31:4529-35 PMCID:PMC3871514

[18] Moreau P,Pégourié B.Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005-01 trial.Blood2011;117:3041-4

[19] Farhan S,Baladandayuthapani V.Response before autologous hematopoietic stem cell transplantation is an important predictor of outcome in multiple myeloma.Blood2011;118:4119

[20] Corso A,Pagnucco G.Blood stem cell collections in multiple myeloma: definition of a scoring system.Bone Marrow Transplant2000;26:283-6

[21] Popat U,Thandi R.Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma.Biol Blood Marrow Transplant2009;15:718-23 PMCID:PMC4352933

[22] Bhutani D,Valent J.Evaluating the effects of lenalidomide induction therapy on peripheral stem cells collection in patients undergoing autologous stem cell transplant for multiple myeloma.Support Care Cancer2013;21:2437-42 PMCID:PMC3837683

[23] Chhabra S,Watts NL.Stem cell mobilization yields with daratumumab- and lenalidomide-containing quadruplet induction therapy in newly diagnosed multiple myeloma: findings from the MASTER and GRIFFIN trials.Transplant Cell Ther2023;29:174.e1-10

[24] Oza S,Vissa P.Effect of daratumumab on stem cell mobilization and engraftment kinetics post autologous stem cell transplantation in patients with newly diagnosed multiple myeloma.Blood2022;140:10441-2

[25] Yoshihara S,Shimizu Y.Feasibility of six cycles of lenalidomide-based triplet induction before stem cell collection for newly diagnosed transplant-eligible multiple myeloma.Hematology2021;26:388-92

[26] Bal S,Shah GL.Stem cell mobilization and autograft minimal residual disease negativity with novel induction regimens in multiple myeloma.Biol Blood Marrow Transplant2020;26:1394-401 PMCID:PMC7371503

[27] Wei X.Stem cell mobilization in multiple myeloma: challenges, strategies, and current developments.Ann Hematol2023;102:995-1009 PMCID:PMC10102143

[28] Atilla P, Bakanay Ozturk SM, Demirer T. How to manage poor mobilizers for high dose chemotherapy and autologous stem cell transplantation?.Transfus Apher Sci2017;56:190-8

[29] Crees ZD,Vainstein A,DiPersio JF.GENESIS: phase III trial evaluating BL-8040 + G-CSF to mobilize hematopoietic cells for autologous transplant in myeloma.Future Oncol2019;15:3555-63 PMCID:PMC7421992

[30] Charalampous C,Gertz M.Impact of the time interval between end of induction and autologous hematopoietic transplantation in newly diagnosed patients with multiple myeloma.Bone Marrow Transplant2023;58:46-53 PMCID:PMC9812760

[31] Engelhardt M,Kleber M.European myeloma network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma.Haematologica2014;99:232-42 PMCID:PMC3912952

[32] Cavo M,Palumbo A.International myeloma working group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation.Blood2011;117:6063-73 PMCID:PMC3293742

[33] Duong HK,Copelan E.Peripheral blood progenitor cell mobilization for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American society for blood and marrow transplantation.Biol Blood Marrow Transplant2014;20:1262-73

[34] DiPersio JF,Nademanee A.Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma.Blood2009;113:5720-6

[35] DiPersio JF,Stiff PJ.Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma.J Clin Oncol2009;27:4767-73

[36] Crees ZD,Jayasinghe RG.Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial.Nat Med2023;29:869-79 PMCID:PMC10115633

[37] FDA approves motixafortide plus filgrastim for stem cell mobilization in multiple myeloma. Available from: https://www.ajmc.com/view/fda-approves-motixafortide-plus-filgrastim-for-stem-cell-mobilization-in-multiple-myeloma [Last accessed on 21 May 2024]

[38] Bekadja MA,Ouldjeriouat H.First experience of the use of a generic of plerixafor in peripheral blood stem cell mobilization in multiple myeloma and lymphoma patients.Transfus Apher Sci2021;60:103070

[39] Sevindik O,Serin I.Comparison of efficacy and safety of generic plerixafor vs original plerixafor in the mobilization of myeloma patients.Blood2022;140:12803-4

[40] Micallef IN,Gastineau DA.Cost-effectiveness analysis of a risk-adapted algorithm of plerixafor use for autologous peripheral blood stem cell mobilization.Biol Blood Marrow Transplant2013;19:87-93

[41] Prakash VS,Sahoo RK.Multiple myeloma: risk adapted use of plerixafor for stem cell mobilization prior to autologous stem cell transplantation is effective and cost efficient.Clin Lymphoma Myeloma Leuk2022;22:44-51

[42] Park G,Stiller T,Yuan S.Dose capping of plerixafor in patients weighing more than 100 kg at one vial led to successful mobilization outcomes and significant cost savings.Transfusion2018;58:323-9

[43] Shah EE,Wong SW.Impact of plerixafor use at different peripheral blood CD34⁺ thresholds on autologous stem cell collection in patients with multiple myeloma.Biol Blood Marrow Transplant2020;26:876-83

[44] Lamotte M,Siegel DS,Serlin PA.EE56 cost-effectiveness analysis of motixafortide on top of G-CSF for stem cell mobilization for autologous bone marrow transplantation in patients with multiple myeloma.Value Health2022;25:S346

[45] Yassine F,Tsalantsanis A.Trends in utilization of stored cryopreserved autologous peripheral hematopoietic cells intended for a second (or beyond) autologous hematopoietic cell transplantation in patients with multiple myeloma: a single center experience.Bone Marrow Transplant2023;58:1130-6 PMCID:PMC10555832

[46] Afifi S,Devlin S.Upfront plerixafor plus G-CSF versus cyclophosphamide plus G-CSF for stem cell mobilization in multiple myeloma: efficacy and cost analysis study.Bone Marrow Transplant2016;51:546-52 PMCID:PMC7337097

[47] Norton J,Hagen P,Stiff PJ.In vivo potency of hematopoietic stem cells after long-term storage at -80C in DMSO+HES cryprotectant mixture: comparing engraftment kinetics and efficacy data in first and second autologous stem cell transplantation in myeloma.Blood2023;142:6779

[48] Giralt S,Harousseau J.International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100).Leukemia2009;23:1904-12

[49] Wuchter P.Processing, cryopreserving and controlling the quality of HSCs. In: Carreras E, Dufour C, Mohty M, Kröger N, editors. The EBMT handbook. Cham: Springer International Publishing; 2019. pp. 127-30.

[50] Aladağ Karakulak E,Büyükaşik Y.CD34⁺ hematopoietic progenitor cell dose as a predictor of engraftment and survival in multiple myeloma patients undergoing autologous stem cell transplantation.Turk J Med Sci2020;50:1851-6 PMCID:PMC7775700

[51] Weaver CH,Birch R.An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy.Blood1995;86:3961-9

[52] Desikan KR,Munshi NC.Preceding chemotherapy, tumour load and age influence engraftment in multiple myeloma patients mobilized with granulocyte colony-stimulating factor alone.Br J Haematol2001;112:242-7

[53] Schulman KA,Zhen B,Weaver CH.Effect of CD34⁺ cell dose on resource utilization in patients after high-dose chemotherapy with peripheral-blood stem-cell support.J Clin Oncol1999;17:1227

[54] Cook G,Cairns DA.The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial.Lancet Haematol2016;3:e340-51

[55] Cook G,Brown JM.High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label, phase 3 trial.Lancet Oncol2014;15:874-85

[56] Gregersen H,Remes K.Carfilzomib and dexamethasone maintenance following salvage ASCT in multiple myeloma: a randomised phase 2 trial by the Nordic Myeloma Study Group.Eur J Haematol2022;108:34-44 PMCID:PMC9292771

[57] Hagen PA.The role of salvage second autologous hematopoietic cell transplantation in relapsed multiple myeloma.Biol Blood Marrow Transplant2019;25:e98-107

[58] Michaelis LC,Zhong X.Salvage second hematopoietic cell transplantation in myeloma.Biol Blood Marrow Transplant2013;19:760-6

[59] Bhutani M.Boosting CAR T cytopenias with backup autologous stem cells.Transplant Cell Ther2023;29:535-6

[60] Rejeski K,Iacoboni G.Severe hematotoxicity after CD19 CAR-T therapy is associated with suppressive immune dysregulation and limited CAR-T expansion.Sci Adv2023;9:eadg3919 PMCID:PMC10516499

[61] Davis JA,Wesson W.Efficacy and safety of CD34⁺ stem cell boost for delayed hematopoietic recovery after BCMA directed CAR T-cell therapy.Transplant Cell Ther2023;29:567-71

[62] Mullanfiroze K,Chu J.CD34⁺-selected stem cell boost can safely improve cytopenias following CAR T-cell therapy.Blood Adv2022;6:4715-8 PMCID:PMC9631677

[63] Künkele A,Beebe A.Manufacture of chimeric antigen receptor T cells from mobilized cyropreserved peripheral blood stem cell units depends on monocyte depletion.Biol Blood Marrow Transplant2019;25:223-32

[64] Ahmed N,Rojas P.Significant costs and low utilization of stored peripheral blood stem cells for salvage autologous transplant in multiple myeloma patients including those meeting mSMART criteria.Bone Marrow Transplant2021;56:1458-61 PMCID:PMC8189914

[65] Chhabra S,Szabo A.Utilization and cost implications of hematopoietic progenitor cells stored for a future salvage autologous transplantation or stem cell boost in myeloma patients.Biol Blood Marrow Transplant2020;26:2011-7

[66] Phipps C,Holmberg LA.Utilization of stored autologous PBSCs to support second autologous transplantation in multiple myeloma patients in the era of novel agent therapy.Bone Marrow Transplant2015;50:663-7